The human microbiota plays an essential role for human health and well-being. By offering human fecal samples, we aim to enable and assist active consideration of the human gut microbiome in development of health-promoting products, drugs and biomarkers by establishing a Biobank of thoroughly evaluated and screened fecal samples.
Our body is home to a gut microflora that consist of 100 trillion microbes and over 2 million microbial genes, weighing up to 2 kg and often referred to as our biome. Our biome is known to play a central role in many physiological functions in our body; it acts as an organ vital to energy release, it takes care of many physiological and mechanical functions vital to our digestion, it is responsible for production of essential vitamins and it is involved in drug metabolism just to name a few recognized effects. In terms of composition our biome is as unique to each of us as is our fingerprints. Our personal biome evolves over time in parallel with the rest of the body.
We are all, with increasing frequency and over time, risking prolonged negative imbalances in our biome. Undesirable changes in our biome can have profound effect on our well-being and health. It is widely recognized that imbalances in the biome can induce inflammation, release toxic substances, trigger immune responses and cause disease and discomfort. Many factors can trigger imbalances, ranging from drugs used to cure potentially fatal diseases to damaging lifestyles and prolonged periods of inappropriate diet.
Because of the essential role of the microbiota for human health, there is an increasing focus on maintaining or re-establishing a healthy and well-functioning microbiota.
BiomCare believe that products to re-establish a well-functioning microbiota will become central for promoting heath and slowing down development of a range of both immune and metabolic conditions. But before these products can become available, they must be thoroughly screened and stored under controlled conditions to ensure the desired effect and safety.
We hope that by furthering our understanding of the gut microbiota, and supporting clinical evaluation of the potential benefits of a healthy microbiome, we can promote new FMT solutions that are both minimally invasive and require less medication such as antibiotics.